Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

Abstract Background Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count < 50,000/µL). Platelet transfusion has been a gold standard for increasing the platelet count to prevent hemorrhagic events in such patients. Lusutrombopag, a thrombopoietin receptor ag...

Full description

Bibliographic Details
Main Authors: Hiroaki Nomoto, Naoki Morimoto, Kouichi Miura, Shunji Watanabe, Yoshinari Takaoka, Hiroshi Maeda, Takahiro Sasaki, Yohei Koyashiki, Hidekazu Kurata, Norikatsu Numao, Norio Isoda, Hironori Yamamoto
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Gastroenterology
Subjects:
Liver cirrhosis
Thrombocytopenia
Thrombopoietin receptor agonist
Platelet transfusion
Online Access:https://doi.org/10.1186/s12876-020-01573-9

Internet

https://doi.org/10.1186/s12876-020-01573-9

Similar Items